An official website of the United States government
Home
Name
Novilase
Alternate Names
Abbreviations
None
Category
Other therapy
Subcategory
None
NSC Number
None
Primary Site
Breast
Histology
None
Remarks
Oct. 1, 2021 The FDA granted Breakthrough Device designation to the Novilase Interstitial Laser System and its proposed indication for use: the focal destruction of malignant breast tumors in adult women seeking a breast conserving procedure.
Novilase uses laser ablation to destroy tumors as an alternative to surgery. The intended use is for the focal destruction of malignant tumors of the breast up to 15 mm; for general surgery procedures including incision, excision, and ablation of soft tissues; and coagulative necrosis and interstitial laser coagulation of soft tissues.
Coding notes: Until we can determine the appropriate treatment field this procedure should be coded in, code in "Other Treatment" and assign code 1.
Novilase uses laser ablation to destroy tumors as an alternative to surgery. The intended use is for the focal destruction of malignant tumors of the breast up to 15 mm; for general surgery procedures including incision, excision, and ablation of soft tissues; and coagulative necrosis and interstitial laser coagulation of soft tissues.
Coding notes: Until we can determine the appropriate treatment field this procedure should be coded in, code in "Other Treatment" and assign code 1.
Coding
Please see remarks for additional information
